Psychotropic drugs intake in people aging with intellectual disability: Prevalence and predictors

被引:14
作者
Garcia-Dominguez, Laura [1 ]
Navas, Patricia [1 ]
Angel Verdugo, Miguel [1 ]
Arias, Victor B. [1 ]
Gomez, Laura E. [2 ]
机构
[1] Univ Salamanca, Inst Community Integrat, Ave Merced 109-131, Salamanca 37005, Spain
[2] Univ Oviedo, Oviedo, Spain
关键词
aging; behavioural problems; intellectual disability; mental health; psychotropic medication; MEDICATION USE; OLDER-ADULTS; CHALLENGING BEHAVIOR; PHARMACOLOGICAL MANAGEMENT; MENTAL-RETARDATION; INDIVIDUALS; DISORDERS; PHARMACOTHERAPY; POPULATION; COMMUNITY;
D O I
10.1111/jar.12996
中图分类号
G44 [教育心理学];
学科分类号
0402 ; 040202 ;
摘要
Background Psychotropic medication is frequently administered to people with intellectual disability with mental health and/or behavioural problems, instead of other non-pharmacological interventions. This study describes the mental health and behavioural problems of people aging with intellectual disability, their psychotropic medication intake, and the factors contributing to a greater medication intake. Method The sample consisted of 991 people with intellectual disability over 45 years. Descriptive statistics and multinominal logistic regression were carried out. Results Antipsychotics were the most used psychotropic drug. Older people with mild intellectual disability living in institutions and affected by mental health and behavioural problems were more likely to take larger amounts of psychotropic medication. Conclusions Antipsychotics continue to be widely used by people with intellectual disability and mental and behavioural health problems, especially those in institutionalised settings. Future research should consider if medication intake could be reduced providing better supports in the community and non-pharmacological interventions.
引用
收藏
页码:1109 / 1118
页数:10
相关论文
共 53 条
  • [1] Social Inclusion and Community Participation of Individuals with Intellectual/Developmental Disabilities
    Amado, Angela Novak
    Stancliffe, Roger J.
    McCarron, Mary
    McCallion, Philip
    [J]. INTELLECTUAL AND DEVELOPMENTAL DISABILITIES, 2013, 51 (05) : 360 - 375
  • [2] American Psychiatric Association, 2022, Diagnostic and statistical manual of mental disorders, V5th ed., text rev., DOI [10.1176/appi.books.9780890425596, DOI 10.1176/APPI.BOOKS.9780890425596]
  • [3] [Anonymous], 2015, NICE GUIDELINES
  • [4] Pharmacotherapy for mood and anxiety disorders in older people with intellectual disability in comparison with the general population
    Axmon, Anna
    El Mrayyan, Nadia
    Eberhard, Jonas
    Ahlstrom, Gerd
    [J]. BMC PSYCHIATRY, 2019, 19 (1)
  • [5] Demographic and diagnostic profiles of older people with intellectual disability and prescription of antipsychotics
    Axmon, Anna
    Ahlstrom, Gerd
    Persson, Rebecca Gagnemo
    Eberhard, Jonas
    [J]. SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY, 2019, 54 (08) : 937 - 944
  • [6] Prescription of potentially inappropriate medications among older people with intellectual disability: a register study
    Axmon, Anna
    Sandberg, Magnus
    Ahlstrom, Gerd
    Midlov, Patrik
    [J]. BMC PHARMACOLOGY & TOXICOLOGY, 2017, 18
  • [7] Prevalence of psychotropic medication use and association with challenging behaviour in adults with an intellectual disability. A total population study
    Bowring, D. L.
    Totsika, V.
    Hastings, R. P.
    Toogood, S.
    McMahon, M.
    [J]. JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2017, 61 (06) : 604 - 617
  • [8] Bratek A, 2017, PSYCHIAT DANUB, V29, pS590
  • [9] Bruininks R.H., 1986, EXAMINERS MANUAL ICA
  • [10] Central nervous system medication use in older adults with intellectual disability: Results from the successful ageing in intellectual disability study
    Chitty, Kate M.
    Evans, Elizabeth
    Torr, Jennifer J.
    Iacono, Teresa
    Brodaty, Henry
    Sachdev, Perminder
    Trollor, Julian N.
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2016, 50 (04) : 352 - 362